Introduction: Gastric cancer remains a critical obstacle for oncologists worldwide, particularly in prevalent regions of high incidence such as East Asia and Latin America — mainly elevated in Brazil’s northern and northeastern states. This prevalence is attributed to GC’s pronounced molecular heterogeneity and the lack of validated prognostic biomarkers. Mutational studies aim to map the genomic alterations present, facilitating the identification of novel oncogenic targets. Furthermore, these alterations often manifest as distinctive mutational patterns — known as mutational signatures — linked to endogenous and exogenous processes. Characterizing these signatures can reveal strategies to mitigate GC’s public?health burden. Accordingly, there is an urgent need for research dedicated to discovering molecular markers that can underpin improved clinical management of the disease. Objective: To investigate the most frequently mutated genes in gastric cancer and to characterize the distribution of mutational signatures, with a particular focus on the molecular peculiarities of a regional Brazilian cohort. Methodology: We analyzed 102 GC tumor samples collected from patients at João de Barros Barreto University Hospital (HUJBB), under ethics approval CEP/HUJBB n. 47580121.9.0000.5634 (Plataforma Brasil). Genomic data curation was performed using Broad Institute pipelines. Somatic variants were called with VarDict. For mutation refinement, we employed two filtering strategies: (i) the criteria defined by Jessen et al. (2021); and (ii) functional impact assessment via SIFT and PolyPhen-2. Filtered mutations were processed with the Maftools R package, and mutational signatures were extracted using the MutationalPatterns package. Results: Filtering strategy (i) yielded 90 high?confidence somatic mutations, while strategy (ii) identified over 99,000 variants subject to functional annotation. The most recurrently altered genes —TXNIP, FTH1, JAK1, CHD4, and DDX5 — are all implicated in tumorigenesis. Established GC?associated genes such as ARID1A, KRAS, CDH1, and APC displayed mutation frequencies consistent with the literature. Notably, TP53 — commonly reported as the top mutated gene in GC —was altered in only 7% of our samples, suggesting a cohort?specific molecular profile. Conversely, CTNNB1 mutations appeared in 21% of cases, exceeding typical GC frequencies. Dominant mutational signatures were SBS5, SBS6, and SBS3. SBS3 is linked to chronic Helicobacter pylori infection, “BRCAness,” and sustained inflammation; SBS6 reflects DNA-repair defects and microsatellite instability (MSI); and SBS5 is ubiquitous across multiple cancers, though its etiology remains incompletely understood. Conclusion: Our analysis revealed recurrent mutations in TXNIP, FTH1, JAK1, CHD4, and DDX5, a high incidence of CTNNB1 alterations, and an unusually low TP53 mutation rate, underscoring the unique molecular landscape of this regional cohort. The predominance of SBS3, SBS5, and SBS6 mutational signatures reflects underlying processes such as inflammation, genomic instability, and DNA repair deficiency, emphasizing the critical importance of region-specific molecular characterization in gastric cancer.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/